GlassScriptPhysician profile
Stephen Lynn Harris
NPI 1821195637
$2,251.13
in general payments reported to CMS, 2019-2025
21 companies · $906 in 2025
The $906 reported for 2025 was more than what 82% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $205 · 2023: $397 · 2024: $744 · 2025: $906.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,047.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,046.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $455.32 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $343.66 | 2023-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $285.92 | 2022-2025 | |
| Pfizer INC. | $272.53 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $158.27 | 2024-2025 | |
| Exact Sciences Corporation | $139.80 | 2023-2025 | Cologuard Collection Kit |
| Lilly USA, LLC | $95.03 | 2022-2025 | Mounjaro, Zepbound, Trulicity |
| Novartis Pharmaceuticals Corporation | $86.30 | 2022-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $70.06 | 2023-2025 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $59.01 | 2024 | Jardiance, Tradjenta |
| Janssen Pharmaceuticals, INC | $55.50 | 2024 | Spravato |
| Verona Pharma, INC. | $43.17 | 2025 | Ohtuvayre |
| Shield Therapeutics INC | $32.13 | 2024 | |
| Phathom Pharmaceuticals, INC. | $27.98 | 2025 | Voquezna |
| Insulet Corporation | $24.13 | 2023 | Omnipod |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $22.00 | 2023 | Gvoke Hypopen |
| Axsome Therapeutics, INC. | $19.50 | 2022 | |
| Viatris Specialty LLC | $16.91 | 2025 | Yupelri |
| Merck Sharp & Dohme LLC | $15.48 | 2023 | Verquvo, Belsomra |
| Amgen INC. | $14.73 | 2024 | Otezla, Repatha |
| Glaxosmithkline, LLC. | $13.70 | 2023 | Trelegy Ellipta, Arexvy, Shingrix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Harris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.